Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine

Stem Cell Research & Therapy

Wan-long Tan²  Qing-jun Chu¹  Yang Luo²  Cheng-yong Lei²  Shi-yu Pang²  Yong-tong Zhu¹ 

[1] Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China

关键词: Streptavidin- interleukin-2;    Vaccine;    Cancer stem cells;    MB49 cells;    Bladder cancer;   

Others  :  1233699
DOI  :  10.1186/s13287-015-0211-1

 received in 2015-08-04, accepted in 2015-10-22,  发布年份 2015

【 摘 要 】

Introduction

In previous study the streptavidin interleukin-2 (SA-IL-2)-modified MB49 vaccine was effective against bladder cancer in a mouse model. However, a small portion of tumors regrew because the vaccine could not eliminate MB49 bladder cancer stem cells (MCSCs). Accordingly, we developed a SA-IL-2-modified MCSCs vaccine and evaluated its antitumor effects.

Methods

MCSCs were isolated and identified in cancer stem cells (CSCs) characters, with high expression of CSCs markers, higher resistance to chemotherapy, greater migration in vitro, and stronger tumorigenicity in vivo. The SA-IL-2 MCSCs vaccine was prepared and its bioactivity was evaluated. The protective, therapeutic, specific and memory immune response in animal experiments were designed to identify whether the vaccine elicited antitumor immunity and acted against metastatic bladder cancer.

Results

MCSCs had higher level of CD133 and CD44, less susceptibility to chemotherapy, more pronounced migration and greater tumorigenic ability. The successfully prepared SA-IL-2 MCSCs vaccine inhibited the tumor volume and prolonged mice survival in animal experiments. The expression of IgG, the population of dendritic cells, CD8 ⁺and CD4 ⁺T cells were highest in the experimental group than in the four control groups.

Conclusions

The SA-IL-2 MCSCs vaccine induced an antitumor immune response and was used to eliminate MCSCs to prevent tumor regrowth.

【 授权许可】

   
2015 Zhu et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 1:9-29.
• [2]Cagiannos I, Morash C: Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J 2009, 6(Suppl 4):S237-42.
• [3]Zhang X, Shi X, Li J, Hu Z, Guo F, Huang X, et al.: Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells. Urology 2011, 3:721-2.
• [4]McDermott SP, Wicha MS: Targeting breast cancer stem cells. Mol Oncol 2010, 5:404-19.
• [5]Zhu YT, Lei CY, Luo Y, Liu N, He CW, Chen W, et al.: A modified method for isolation of bladder cancer stem cells from a MB49 murine cell line. BMC Urol 2013, 13:57. BioMed Central Full Text
• [6]Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, et al.: Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013, 9:1499-509.
• [7]Li L, Li B, Shao J, Wang X: Chemotherapy sorting can be used to identify cancer stem cell populations. Mol Biol Rep 2012, 11:9955-63.
• [8]Brescia P, Richichi C, Pelicci G: Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol 2012, 2012:376894.
• [9]Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, et al.: Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci 2011, 21:3589-605.
• [10]Ou J, Deng J, Wei X, Xie G, Zhou R, Yu L, et al.: Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. Stem Cell Res 2013, 2:820-33.
• [11]Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-84.
• [12]Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 10:755-68.
• [13]Sung JM, Cho HJ, Yi H, Lee CH, Kim HS, Kim DK, et al.: Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008, 1:163-7.
• [14]Okamoto A, Chikamatsu K, Sakakura K, Hatsushika K, Takahashi G, Masuyama K: Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 2009, 7:633-9.
• [15]Lobo NA, Shimono Y, Qian D, Clarke MF: The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23:675-99.
• [16]Fleetwood AJ, Cook AD, Hamilton JA: Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 2005, 5:405-28.
• [17]Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q: Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 2012, 2:167-77.
• [18]Weng D, Song B, Koido S, Calderwood SK, Gong J: Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation. J Immunol 2013, 2:755-63.
• [19]Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, et al.: Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006, 21:10247-52.